ipilimumab/nivolumab combination provided a nearly 60% increase in progression-free survival (PFS) relative to ipilimumab alone. Drawn from a Phase III trial called CheckMate 067, the data were characterized as setting a new treatment standard.
MRV Research
‘Something weird’ may lead to melanoma breakthrough
Western researchers look to take metastatic melanoma survival rates from a gloomy 5 per cent five years after diagnosis to almost 100 per cent, by simply looking where others haven’t.
Primary Melanoma Treatment Outcome Factors Identified
Sex, normal pretreatment serum lactate dehydrogenase (LDH) level, BRAF genotype, and primary melanoma ulceration status were identified as being independent factors associated with treatment outcomes in patients with melanoma, according to an article published online in the journal Cancer.
Long-Term Survival Possible With MAPK Inhibition in BRAF-Mutant Melanoma –
Long-term outcomes for BRAF-mutant melanoma patients treated with BRAF and MEK inhibitors are influenced by a number of baseline factors including BRAF genotype, gender, and serum lactate dehydrogenase (LDH) levels, according to a new study.